CMPX - CIK 0001738021
Compass Therapeutics, Inc. (CMPX) reported net income of -$66.49M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$66.49M | -34.7% |
| FY 2024 | -$49.38M | -16.2% |
| FY 2023 | -$42.49M | -8.3% |
| FY 2022 | -$39.23M | +52.3% |
| FY 2021 | -$82.18M | -178.6% |
| FY 2020 | -$29.50M | +15.1% |
| FY 2019 | -$34.74M | -96312.0% |
| FY 2019 | -$36.04K | - |
Compass Therapeutics, Inc. (CMPX) reported net income of -$66.49M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Compass Therapeutics, Inc.'s net income declined from -$36.04K to -$66.49M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.